Last reviewed · How we verify

UNICANCER — Portfolio Competitive Intelligence Brief

UNICANCER pipeline: 3 marketed, 0 filed, 11 Phase 3, 16 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 11 Phase 3 16 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Capecitabine tablets Capecitabine tablets marketed Fluoropyrimidine antimetabolite Thymidylate synthase Oncology
5-fluoro-uracil 5-fluoro-uracil marketed Antimetabolite Thymidylate synthase; RNA and DNA incorporation Oncology
Folinic Acid Folinic Acid marketed
L-folinic L-folinic phase 3 Reduced folate cofactor / Chemotherapy adjuvant Thymidylate synthase (indirect) Oncology
Fulvestrant Prefilled Syringe Fulvestrant Prefilled Syringe phase 3 Selective estrogen receptor degrader (SERD) Estrogen receptor alpha (ERα) Oncology
CHEMOTHERAPY then HORMONOTHERAPY CHEMOTHERAPY then HORMONOTHERAPY phase 3 Combination chemotherapy and endocrine therapy regimen Oncology
HIPEC HIPEC phase 3 Regional chemotherapy delivery system with hyperthermia Oncology
177Lu-PMSA-617 177Lu-PMSA-617 phase 3 Radioligand therapy PSMA (prostate-specific membrane antigen) Oncology
Nivolumab Injection Nivolumab Injection phase 3 PD-1 inhibitor PD-1 (Programmed Death-1) Oncology
AC regimen AC regimen phase 3 Chemotherapy combination (anthracycline + alkylating agent) DNA (topoisomerase II and DNA alkylation) Oncology
mFolfox6 or capecitabine mFolfox6 or capecitabine phase 3 pyrimidine analog Oncology
IV Chemotherapy (Regimen 1) IV Chemotherapy (Regimen 1) phase 3 Chemotherapy combination regimen Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 4 shared drug classes
  2. Asan Medical Center · 4 shared drug classes
  3. Hoffmann-La Roche · 3 shared drug classes
  4. AstraZeneca · 3 shared drug classes
  5. Bio-Thera Solutions · 2 shared drug classes
  6. Bristol-Myers Squibb · 2 shared drug classes
  7. Celltrion · 2 shared drug classes
  8. Amgen · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for UNICANCER:

Cite this brief

Drug Landscape (2026). UNICANCER — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/unicancer. Accessed 2026-05-13.

Related